Dan Joyce
@DDJoyce_BFA
Assistant Professor - Urologic Oncologist @VUMCurology. HSR: Cost + financial toxicity. Former Mayo Clinic fellow and VUMC resident. Views are my own. RT≠E
With the final analysis of the last of the 1st line metastatic clear cell RCC trials combination trials it’s still fair to say ‘pick one and use it well’. #GUARDSymposium2025 Ipi/nivo is less good at getting initial control but has less long term toxicity. @brian_rini @OncoAlert
Cost-Effectiveness of Therapies for Muscle-Invasive Bladder Cancer jamanetwork.com/journals/jaman…
Trimodal therapy was associated with improved quality of life, but was not a cost-effective strategy for management of muscle-invasive bladder cancer relative to radical cystectomy. ja.ma/43XxR42
📢 New publication alert! @SWilliams_MD and the expert team at @UTMBHealth @UTMBUrology share critical insights in @JAMANetworkOpen on cost effectiveness for advanced bladder cancer treatments. 🔗 Read the full study: jamanetwork.com/journals/jaman… #UroOnc #BladderCancer #JAMA
jamanetwork.com/journals/jaman… TMT for MIBC is a crucial treatment option for our patients. 💵However, its current costs are unsustainable, especially with the growing interest in expanding its use.
Viewpoint: Cabozantinib capsules are more cost-effective than tablets for treating various cancers, and adopting capsule-based dosing strategies could reduce costs while maintaining efficacy. ja.ma/4l4zJ0o
Perspective by Thomas J. Hwang, MD (@thomasmd), Nancy L. Keating, MD, MPH, and Stacie B. Dusetzina, PhD: Biologic Drugs and Medicare Price Negotiation nej.md/44egmLM #HealthPolicy
⬆️ Elevated levels of kidney injury molecule-1 (KIM-1) may serve as a prognostic biomarker for patients with metastatic #RCC, according to data presented at @ASCO #ASCO25: buff.ly/h4XKFgm 🔎 The analysis demonstrated that elevated levels of KIM-1 at baseline were…
📺 @ReubenBenDavid1 of @IcahnMountSinai, and Daniel Joyce, MD, of @VUMCDiscoveries, share the reasoning and findings of an analysis on the pathological and clinical features associated with preoperatively detectable #ctDNA: buff.ly/BZG3im3
🔊 Drs. Sam Chang (@UroCancerMD) and Daniel Joyce of @VUMCDiscoveries sit down to take a comprehensive look at the latest QUILT-3.032 study: buff.ly/4NLcmoO 📺 The doctors discuss topics including complete responses to N-803 plus #BCG in patients with BCG-unresponsive…
I can genuinely say that this resource is hands down the best out there for boards studying. It has everything you need. An awesome accomplishment by Ben Dropkin
Congratulations to all the newly @ABUrology Board Certified urologists! An enormous achievement many years in the making 👏🍾
National complication and cost burden of TURBT @UclaUrology @MayoUrology @VMUrology @VUMCurology @UTMBUrology sciencedirect.com/science/articl…
Save the Date for the #VUS2025 Annual Meeting, September 29-30, 2025 in Nashville, Tennessee! Join urology professionals and students to gain the latest insights from world-class speakers and panels, while connecting and socializing with VUS colleagues and peers. #VUS #urology
KIM-1, linked to immune biology, appears the best prognosis biomarker for kidney cancer. A ⬇️ at 3 wks is higher for sunitinib than ipi/nivo but the fall predicts responses to ipi/nivo only. We should start exploring this circulating marker for prognosis and immune therapy #GU25
📣 Attention @UroOnc applicants! Apply now for the @MayoUrology Urologic Oncology Fellowship in Rochester, MN for the 2026 match! 🗓️ Application deadline February 1, 2025 Apply here: bit.ly/415tB1n @SUO_YUO
📢 Attention @UroOnc applicants! The @MayoUrology Urologic Oncology Fellowship in Rochester, MN is now open for applications for the 2026 match. 🗓️Application Deadline: February 1, 2025 Apply here: bit.ly/415tB1n @SUO_YUO
Great people, great place. Formative experience in my training. Best SUO clinical training there is!
📢 Attention @UroOnc applicants! The @MayoUrology Urologic Oncology Fellowship in Rochester, MN is now open for applications for the 2026 match. 🗓️Application Deadline: February 1, 2025 Apply here: bit.ly/415tB1n @SUO_YUO
Advanced #ProstateCancer: Understanding out-of-pocket medication costs. Daniel Joyce, MD, MS joins @RuchikaTalwarMD @VUMCurology in this important discussion on the financial impact of advanced #PCa treatments on patients. #WatchNow on UroToday > bit.ly/3ADoASf